What one share of Gri Bio holds
We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders.
Gri Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$11.65 |
|---|---|
| Cash and investments | $5.01 |
| Book value | $4.70 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2025 | — | −$121.80 | $0.03 | −$103.80 | — | $12.07 |
Common questions about Gri Bio
How much does one share of Gri Bio earn?
Over the last 12 months, Gri Bio lost $11.65 for each share.
Does Gri Bio pay a dividend?
Gri Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Gri Bio’s book value per share?
Gri Bio’s book value is $4.70 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Gri Bio have?
Each share of Gri Bio has $5.01 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.